Medpace Holdings, Inc. (NASDAQ:MEDP) Holdings Lowered by Axa S.A.

AXA S.A. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 30.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,900 shares of the company's stock after selling 9,858 shares during the quarter. AXA S.A. owned about 0.07% of Medpace worth $7,608,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in Medpace in the 4th quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace in the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares during the period. Lindbrook Capital LLC lifted its position in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Medpace stock traded up $9.09 during trading hours on Monday, hitting $305.12. The stock had a trading volume of 78,166 shares, compared to its average volume of 345,747. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The stock has a market capitalization of $8.77 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 3.81 and a beta of 1.55. The stock's fifty day moving average is $306.90 and its two-hundred day moving average is $328.59.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period last year, the company earned $3.20 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent analyst reports. Truist Financial dropped their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Finally, Leerink Partnrs upgraded Medpace to a "hold" rating in a research report on Monday, March 24th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $349.30.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.